Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benign prostatic hyperplasia: pathophysiology and pharmacological treatment

F A Madsen1, R C Bruskewitz

  • 1Division of Urology, University of Wisconsin Hospital and Clinics, Madison, USA.

Current Opinion in Nephrology and Hypertension
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical and nonsurgical invasive treatment of benign prostatic hyperplasia.

Drugs of today (Barcelona, Spain : 1998)·2004
Same author

Economics of transurethral thermotherapy of the prostate.

World journal of urology·2002
Same author

Correlates of urinary symptom scores in men.

American journal of public health·1999
Same author

The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamic parameters: analysis of the United States randomized study.

The Journal of urology·1999
Same author

Impact of drug therapy on benign prostatic hyperplasia-specific quality of life.

Urology·1999
Same author

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group.

Urology·1999
Same journal

Updates in management of cardiorenal syndrome.

Current opinion in nephrology and hypertension·2026
Same journal

Sex differences in renal acid-base regulation.

Current opinion in nephrology and hypertension·2026
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
See all related articles

Alpha-blocker and antihormonal therapies are effective and safe for symptomatic benign prostatic hyperplasia. Clinical response to these treatments lasts at least 3 years with no increased side effects.

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition in aging men.
  • Symptomatic BPH significantly impacts quality of life.
  • Effective and safe medical therapies are crucial for managing BPH.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of alpha-blocker and antihormonal therapies for symptomatic benign prostatic hyperplasia.
  • To assess the duration of clinical response and the incidence of side effects over a 3-year period.

Main Methods:

  • Review of recent studies and new data on alpha-blocker and antihormonal therapies.
  • Analysis of clinical response and side effect profiles in patients with symptomatic BPH.

Main Results:

Related Experiment Videos

  • Alpha-blocker therapy and antihormonal therapy are confirmed effective and safe for symptomatic BPH.
  • Clinical response to medical therapy persists for at least 3 years.
  • No increase in side effects was observed during the 3-year treatment period.

    • Conclusions:

    • Alpha-blocker and antihormonal therapies offer a durable and safe treatment option for symptomatic BPH.
    • These medical therapies provide sustained symptom relief for at least 3 years.
    • Long-term use of these treatments is associated with a favorable safety profile.